<DOC>
	<DOCNO>NCT01430910</DOCNO>
	<brief_summary>This randomise study divide 2 part . Part A investigates effect prolong dosing ( ten day ) Avibactam Ceftazidime give together effect much Avibactam Ceftazidime enters blood . Part B investigate much Avibactam ( NXL104 ) Ceftazidime enter blood Avibactam Ceftazidine give separately together intravenously .</brief_summary>
	<brief_title>A Study Assess Levels Two Antibiotics Blood When Given Together Separately</brief_title>
	<detailed_description>A Phase I , 2-Part , Open-Label , Pharmacokinetic Drug-Drug Interaction Study CAZ104 ( Avibactam Ceftazidime Healthy Subjects )</detailed_description>
	<mesh_term>Ceftazidime</mesh_term>
	<mesh_term>Avibactam</mesh_term>
	<criteria>Provision sign date , write informed consent prior study specific procedure Healthy male female subject age 18 50 year vein suitable cannulation repeat venepuncture ; female subject must postmenopausal surgically sterile . Female subject must negative pregnancy test screen admi Male subject willing use barrier contraception ie , condom , dose 3 month dose IP ( investigational product ) . Have body mass index ( BMI ) 19 30 kg/m2 As judged Investigator , subject must able understand willing comply study procedure , restriction requirement History clinically significant disease disorder , opinion Investigator , may either put subject risk participation study , influence result subject 's ability participate study History presence gastrointestinal , hepatic renal disease , condition know interfere absorption , distribution , metabolism , excretion drug History severe allergy/hypersensitivity ongoing allergy/hypersensitivity , judge Investigator history hypersensitivity drug similar chemical structure class avibactam , ceftazidime , and/or excipients Any clinically significant illness , medical/surgical procedure trauma within 4 week first administration IP Prolonged QTcF ( &gt; 450 m ) shorten QTcF ( &lt; 350 m ) family history long QT syndrome</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>open label</keyword>
	<keyword>ceftazidime</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>urinary tract infection</keyword>
	<keyword>intra-abdominal infection</keyword>
</DOC>